Comparative Pharmacology
Head-to-head clinical analysis: NESINA versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NESINA versus SITAGLIPTIN PHOSPHATE METFORMIN HYDROCHLORIDE.
NESINA vs SITAGLIPTIN PHOSPHATE; METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion and decreasing glucagon secretion. Metformin is a biguanide that reduces hepatic glucose production, decreases intestinal glucose absorption, and improves insulin sensitivity.
25 mg orally once daily.
Oral, 50 mg sitagliptin/500 mg metformin twice daily or 50 mg sitagliptin/1000 mg metformin twice daily, individually titrated based on glycemic response and tolerability. Maximum daily dose: sitagliptin 100 mg, metformin 2000 mg.
None Documented
None Documented
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Sitagliptin: 12.4 h; metformin: 6.2 h (prolonged in renal impairment).
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Renal: sitagliptin ~87% unchanged in urine; metformin ~90% unchanged in urine. Biliary/fecal: minimal.
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor